WEKO3
インデックスリンク
アイテム
{"_buckets": {"deposit": "62c1a5ad-56a9-4e94-b40a-fb0a19b3a991"}, "_deposit": {"created_by": 3, "id": "14831", "owners": [3], "pid": {"revision_id": 0, "type": "depid", "value": "14831"}, "status": "published"}, "_oai": {"id": "oai:kanazawa-u.repo.nii.ac.jp:00014831", "sets": ["1135"]}, "author_link": ["26568", "26567", "26569", "26566", "26564", "531", "26565"], "item_4_biblio_info_8": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2006-01-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "173", "bibliographicPageStart": "168", "bibliographicVolumeNumber": "59", "bibliographic_titles": [{"bibliographic_title": "Japanese Journal of Infectious Diseases"}]}]}, "item_4_description_21": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The prevalence of adult HIV/AIDS in Thailand is declining due to intense prevention strategies, but it still continues to be a critical health problem with a prevalence of 1.5%. Several HIV vaccine candidates for the prevention of HIV infection or progress to AIDS were examined in clinical trials. We evaluated the cost-effectiveness of a vaccination regimen (rBCG prime-rDIs boost) currently in its pre-clinical phase. The cost-effectiveness of three interventions (vaccination, highly active antiretroviral treatment [HAART], and the combination of the two) through an existing vaccination program was assessed in a Markov model. The disability-adjusted life year (DALY) was the main effectiveness measure. In the base case the efficacy of the vaccine for preventing HIV infection was assumed to be 30%. The cost of the vaccine was estimated on the basis of its predicted production capacities in Thailand. The incremental cost-effectiveness ratios of vaccination, HAART, and the combination were about $US 75, $US 610, and $US 267 per DALY averted compared with the do-nothing strategy in the base case. The HAART-only strategy seemed to be less cost-effective than the other options under the current assumptions. Sensitivity analyses indicated that the new HIV infection rate and the vaccine efficacy could affect the results.", "subitem_description_type": "Abstract"}]}, "item_4_description_5": {"attribute_name": "提供者所属", "attribute_value_mlt": [{"subitem_description": "東京大学大学院薬学系研究科 医薬品評価科学講座", "subitem_description_type": "Other"}, {"subitem_description": "元・金沢大学大学院自然科学研究科", "subitem_description_type": "Other"}]}, "item_4_publisher_17": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "国立感染症研究所"}]}, "item_4_publisher_19": {"attribute_name": "出版者(別名)", "attribute_value_mlt": [{"subitem_publisher": "National Institute of Infectious Diseases"}]}, "item_4_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1344-6304", "subitem_source_identifier_type": "ISSN"}]}, "item_4_version_type_25": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Ono, Shunsuke"}], "nameIdentifiers": [{"nameIdentifier": "26564", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "40345591", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000040345591"}]}, {"creatorNames": [{"creatorName": "Kurotani, Takako"}], "nameIdentifiers": [{"nameIdentifier": "26565", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakasone, Tadashi"}], "nameIdentifiers": [{"nameIdentifier": "26566", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Honda, Mitsuo"}], "nameIdentifiers": [{"nameIdentifier": "26567", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Boon-Long, Jotika"}], "nameIdentifiers": [{"nameIdentifier": "26568", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sawanpanyalert, Pathom"}], "nameIdentifiers": [{"nameIdentifier": "26569", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "木村, 和子"}], "nameIdentifiers": [{"nameIdentifier": "531", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "80324094", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=80324094"}, {"nameIdentifier": "80324094", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000080324094"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-10-03"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "ME-PR-ONO-S-168.pdf", "filesize": [{"value": "76.8 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 76800.0, "url": {"label": "ME-PR-ONO-S-168.pdf", "url": "https://kanazawa-u.repo.nii.ac.jp/record/14831/files/ME-PR-ONO-S-168.pdf"}, "version_id": "d60ecf74-c9e3-40d7-8c8a-e7aaf67d55d0"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand"}]}, "item_type_id": "4", "owner": "3", "path": ["1135"], "permalink_uri": "http://hdl.handle.net/2297/5508", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-10-03"}, "publish_date": "2017-10-03", "publish_status": "0", "recid": "14831", "relation": {}, "relation_version_is_last": true, "title": ["Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand"], "weko_shared_id": 3}
Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand
http://hdl.handle.net/2297/5508
http://hdl.handle.net/2297/5508c582e042-071b-4ebf-9e94-a19c1711140d
名前 / ファイル | ライセンス | アクション |
---|---|---|
ME-PR-ONO-S-168.pdf (76.8 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-10-03 | |||||
タイトル | ||||||
タイトル | Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Ono, Shunsuke
× Ono, Shunsuke× Kurotani, Takako× Nakasone, Tadashi× Honda, Mitsuo× Boon-Long, Jotika× Sawanpanyalert, Pathom× 木村, 和子 |
|||||
提供者所属 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 東京大学大学院薬学系研究科 医薬品評価科学講座 | |||||
提供者所属 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 元・金沢大学大学院自然科学研究科 | |||||
書誌情報 |
Japanese Journal of Infectious Diseases 巻 59, 号 3, p. 168-173, 発行日 2006-01-01 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1344-6304 | |||||
出版者 | ||||||
出版者 | 国立感染症研究所 | |||||
出版者(別名) | ||||||
出版者 | National Institute of Infectious Diseases | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The prevalence of adult HIV/AIDS in Thailand is declining due to intense prevention strategies, but it still continues to be a critical health problem with a prevalence of 1.5%. Several HIV vaccine candidates for the prevention of HIV infection or progress to AIDS were examined in clinical trials. We evaluated the cost-effectiveness of a vaccination regimen (rBCG prime-rDIs boost) currently in its pre-clinical phase. The cost-effectiveness of three interventions (vaccination, highly active antiretroviral treatment [HAART], and the combination of the two) through an existing vaccination program was assessed in a Markov model. The disability-adjusted life year (DALY) was the main effectiveness measure. In the base case the efficacy of the vaccine for preventing HIV infection was assumed to be 30%. The cost of the vaccine was estimated on the basis of its predicted production capacities in Thailand. The incremental cost-effectiveness ratios of vaccination, HAART, and the combination were about $US 75, $US 610, and $US 267 per DALY averted compared with the do-nothing strategy in the base case. The HAART-only strategy seemed to be less cost-effective than the other options under the current assumptions. Sensitivity analyses indicated that the new HIV infection rate and the vaccine efficacy could affect the results. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 |